Noregen, a regenerative medicine ocular therapeutic
Ended Project Grant Awarded Last action
- Award ID
- R44EY030807
- Recipient
-
Caeregen Therapeutics LLC UEI ZZY2CNNLJ2D1
- Awarding agency
-
National Eye Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,155,749
Award facts
- Assistance listing
- 93.867 Vision Research
- Completion date
- Place of performance
- Rochester, MI, USA
Award details come from USAspending.gov.
Description
- Abstract
- Ischemic retinopathies, such as diabetic retinopathy and retinal vein occlusion, are the leading cause of blindness in the united states. Common features are leaky vessels, swelling, capillary drop out, aberrant vessel growth and retinal detachment. Current treatments include laser ablation, anti-vegfs and steroids. All are sub-optimal and only serve to slow disease progression and vision loss, and do not repair or regenerate the damaged vessels. Laser treatment is used to ablate avascular/ischemic regions of the retina to reduce the hypoxic drive which causes the abnormal vascular permeability, exudation and neovascularization. Anti-vegfs and steroids transiently reduce vascular permeability but do not aid in normal retinal blood vessel repair or regeneration. However, the current product, noregen (a norrin derived growth factor) restores vessel integrity and regenerates new non- fenestrated capillaries. Proof of principal was established in the most widely employed animal model for ischemic retinopathies, the mouse oxygen induced retinopathy (OIR) model. In this phase II project, we will optimize dosing of intravitreal injections, create and qualify analytical methods that will be used to establish product release criteria, and run preliminary pharmacokinetics studies to support an FDA IND submission. The long term goal of this project is to create a novel therapy for ischemic retinopathies that will restore the retina rather than simply slow pathology and vision loss.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $720,183 | |
| Amendment | $717,783 | |
| Original award | $717,783 |
Quick answers
Who received award R44EY030807?
R44EY030807 was awarded to Caeregen Therapeutics LLC by National Eye Institute (National Institutes of Health) on September 1, 2019.
How much is award R44EY030807 worth?
$2,155,749 has been obligated on R44EY030807.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award